MEGAN ERBES: Open Payments
NPI 1558933432 · GOODYEAR, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,514 in 77 payments from 18 companies in 2025. Trend: 2023 $1,108 · 2024 $1,493 · 2025 $1,514
Food & beverage: $1,414Education: $100
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 14 | $241 |
| AstraZeneca Pharmaceuticals LP | 4 | $215 |
| Astellas Pharma US Inc | 4 | $194 |
| Novo Nordisk Inc | 14 | $158 |
| ABBVIE INC. | 9 | $135 |
| Lilly USA, LLC | 9 | $120 |
| Bayer Healthcare Pharmaceuticals Inc. | 5 | $90 |
| Corcept Therapeutics | 3 | $71 |
| Abbott Laboratories | 2 | $48 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $45 |
Products named: TRELEGY ELLIPTA, FARXIGA, UBRELVY, Veozah, Kerendia, Ozempic, MOUNJARO, Korlym.
Industry payments across AZ — which companies pay providers there.
